MX9804009A - Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8. - Google Patents
Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.Info
- Publication number
- MX9804009A MX9804009A MX9804009A MX9804009A MX9804009A MX 9804009 A MX9804009 A MX 9804009A MX 9804009 A MX9804009 A MX 9804009A MX 9804009 A MX9804009 A MX 9804009A MX 9804009 A MX9804009 A MX 9804009A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- inhibition
- tumor growth
- antisense oligonucleotides
- oligonucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen oligonucleotidos que son efectivos para inhibir el crecimiento, la metástasis y/o la angiogénesis de tumores, incluyendo particularmente melanoma y/o cáncer pulmonar. También se proveen métodos para utilizar estos oligonucleotidos en el tratamiento de enfermedades.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56130295A | 1995-11-21 | 1995-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9804009A true MX9804009A (es) | 1998-11-29 |
Family
ID=24241411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9804009A MX9804009A (es) | 1995-11-21 | 1998-05-20 | Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8. |
Country Status (14)
Country | Link |
---|---|
US (2) | US5849903A (es) |
EP (1) | EP0879241A4 (es) |
JP (1) | JPH11507245A (es) |
KR (1) | KR19990071523A (es) |
CN (1) | CN1202900A (es) |
AU (1) | AU708096B2 (es) |
CA (1) | CA2236825A1 (es) |
CZ (1) | CZ154898A3 (es) |
EA (1) | EA000841B1 (es) |
MX (1) | MX9804009A (es) |
PL (1) | PL326674A1 (es) |
SI (1) | SI9620122A (es) |
SK (1) | SK66098A3 (es) |
WO (1) | WO1997019097A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033977A1 (en) * | 1990-08-14 | 2004-02-19 | Bennett C. Frank | Oligonucleotide modulation of cell adhesion |
KR100530278B1 (ko) * | 1997-02-28 | 2006-04-06 | 동국제약 주식회사 | 아시아트산 유도체를 유효성분으로 하는 간 보호 및치료제 |
US7332270B1 (en) | 1997-03-24 | 2008-02-19 | Urocor, Inc. | Diagnosis of disease state using mRNA profiles in peripheral leukocytes |
US6190857B1 (en) * | 1997-03-24 | 2001-02-20 | Urocor, Inc. | Diagnosis of disease state using MRNA profiles in peripheral leukocytes |
EP2009109A1 (en) | 1998-01-12 | 2008-12-31 | Pedro Jose | G protein-related kinase mutants in essential hypertension |
US20040043948A1 (en) * | 2001-09-24 | 2004-03-04 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin 8 expression |
JP2003515525A (ja) * | 1999-04-06 | 2003-05-07 | イースト カロライナ ユニバーシティ | 気管支収縮、肺炎、アレルギーおよびサーファクタント枯渇と関連する気道障害を治療するための、低アデノシンアンチセンスオリゴヌクレオチド、その組成物、キットならびにその方法 |
EP1238070B1 (en) * | 1999-12-13 | 2007-08-15 | Bioniche Life Sciences Inc. | Therapeutically useful synthetic oligonucleotides |
WO2001047518A1 (en) * | 1999-12-23 | 2001-07-05 | Childrens Hospital Los Angeles Research Institute | Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant emap ii |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
AU9684601A (en) | 2000-10-12 | 2002-04-22 | Univ Rochester | Compositions that inhibit proliferation of cancer cells |
WO2002066070A1 (fr) * | 2001-02-20 | 2002-08-29 | Anges Mg, Inc. | Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe |
IL159722A0 (en) * | 2001-07-10 | 2004-06-20 | Oligos Etc Inc | Pharmaceutical compositions containing oligonucleotides |
EP2363405A1 (en) | 2002-02-06 | 2011-09-07 | Stasys Technologies, Inc. | Anti-infarction molecules |
EP1534729A2 (en) * | 2002-02-26 | 2005-06-01 | University of Utah Research Foundation | Variants of nedd4l associated with hypertension and viral budding |
CA2495478A1 (en) | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
CN100537761C (zh) * | 2003-11-07 | 2009-09-09 | 中国人民解放军军事医学科学院放射医学研究所 | 反义寡核苷酸,含它们的药物组合及其用于治疗癌症的用途 |
EP1744761A4 (en) * | 2004-04-28 | 2010-01-13 | Molecules For Health Inc | METHOD FOR THE TREATMENT OR PREVENTION OF RESTENOSIS AND OTHER PROLIFERATIVE VASCULAR DISORDER |
AU2006226733C9 (en) | 2005-03-23 | 2019-03-14 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
US7476733B2 (en) * | 2005-03-25 | 2009-01-13 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease |
EP2392645A1 (en) | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
CN100376680C (zh) * | 2005-11-01 | 2008-03-26 | 暨南大学 | 双重靶效应基因嵌合重组体及其构建方法和应用 |
EP2560001B1 (en) | 2006-09-21 | 2016-04-13 | University of Rochester | Compositions and methods related to protein displacement therapy for myotonic distrophy |
EP2104516B1 (en) | 2006-11-01 | 2015-01-07 | University of Rochester | Methods and compositions related to the structure and function of apobec3g |
US7994130B2 (en) | 2006-12-11 | 2011-08-09 | University Of Utah Research Foundation | Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability |
CN101275134B (zh) * | 2007-04-20 | 2010-06-02 | 清华大学深圳研究生院 | 治疗乳腺癌的药物及其专用反义寡核苷酸 |
EP2030615A3 (en) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
EP2195331B1 (en) | 2007-08-28 | 2013-11-20 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
WO2010070380A2 (en) | 2007-12-03 | 2010-06-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | Doc1 compositions and methods for treating cancer |
EP2853897A1 (en) | 2008-05-08 | 2015-04-01 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
WO2010019963A2 (en) | 2008-08-15 | 2010-02-18 | Georgetown University | Na channels, disease, and related assays and compositions |
EP2370080A1 (en) | 2008-12-02 | 2011-10-05 | University of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
US20110060000A1 (en) | 2009-09-10 | 2011-03-10 | Maurizio Grimaldi | Acridine analogs in the treatment of gliomas |
US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
WO2014093688A1 (en) | 2012-12-12 | 2014-06-19 | 1Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
US10441637B2 (en) | 2013-11-21 | 2019-10-15 | Sena Research, Inc. | Methods for structural determination of selenium derivatized nucleic acid complexes |
EP3189069A4 (en) | 2014-07-31 | 2018-03-07 | UAB Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
CN109563516B (zh) | 2016-07-28 | 2023-10-27 | 雷杰纳荣制药公司 | Gpr156变体及其用途 |
AU2017306422A1 (en) | 2016-08-03 | 2019-01-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TLR9 targeted therapeutics |
WO2018136702A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
CA3065938A1 (en) | 2017-06-05 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | B4galt1 variants and uses thereof |
JP7237064B2 (ja) | 2017-09-06 | 2023-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 単一免疫グロブリンインターロイキン-1受容体関連(sigirr)変異型及びその使用 |
WO2019051033A1 (en) | 2017-09-07 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | VARIANTS OF MEMBER 1 OF SOLUT TRANSPORTER FAMILY 14 (SLC14A1) AND USES THEREOF |
US12016314B2 (en) | 2017-09-08 | 2024-06-25 | Ohio State Innovation Foundation | MicroRNA inhibitor therapy in systemic lupus erythematosus |
KR20240125690A (ko) | 2017-10-11 | 2024-08-19 | 리제너론 파마슈티칼스 인코포레이티드 | Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해 |
RU2020115869A (ru) | 2017-10-16 | 2021-11-19 | Ридженерон Фармасьютикалз, Инк. | Варианты корнулина (crnn) и их применение |
US10752682B2 (en) | 2017-11-01 | 2020-08-25 | Nantbio, Inc. | Anti-IL8 antibodies |
US11957687B2 (en) | 2019-07-02 | 2024-04-16 | Regeneron Pharmaceuticals, Inc. | Modulators of HSD17B13 and methods of use thereof |
WO2024173343A1 (en) | 2023-02-14 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Compounds targeting hydroxysteroid 17-beta dehydrogenase (hsd17b) and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5135917A (en) * | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
-
1996
- 1996-11-16 CZ CZ981548A patent/CZ154898A3/cs unknown
- 1996-11-16 JP JP9519806A patent/JPH11507245A/ja active Pending
- 1996-11-16 WO PCT/US1996/018406 patent/WO1997019097A1/en not_active Application Discontinuation
- 1996-11-16 SI SI9620122A patent/SI9620122A/sl unknown
- 1996-11-16 CA CA002236825A patent/CA2236825A1/en not_active Abandoned
- 1996-11-16 EA EA199800391A patent/EA000841B1/ru not_active IP Right Cessation
- 1996-11-16 KR KR1019980703795A patent/KR19990071523A/ko not_active Application Discontinuation
- 1996-11-16 PL PL96326674A patent/PL326674A1/xx unknown
- 1996-11-16 CN CN96198451A patent/CN1202900A/zh active Pending
- 1996-11-16 EP EP96941369A patent/EP0879241A4/en not_active Withdrawn
- 1996-11-16 SK SK660-98A patent/SK66098A3/sk unknown
- 1996-11-16 AU AU10531/97A patent/AU708096B2/en not_active Ceased
-
1997
- 1997-02-05 US US08/796,031 patent/US5849903A/en not_active Expired - Fee Related
-
1998
- 1998-04-06 US US09/055,913 patent/US6017898A/en not_active Expired - Fee Related
- 1998-05-20 MX MX9804009A patent/MX9804009A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SK66098A3 (en) | 1998-11-04 |
US5849903A (en) | 1998-12-15 |
CA2236825A1 (en) | 1997-05-29 |
EA000841B1 (ru) | 2000-04-24 |
AU708096B2 (en) | 1999-07-29 |
SI9620122A (sl) | 1999-04-30 |
CZ154898A3 (cs) | 1998-09-16 |
AU1053197A (en) | 1997-06-11 |
CN1202900A (zh) | 1998-12-23 |
PL326674A1 (en) | 1998-10-12 |
US6017898A (en) | 2000-01-25 |
KR19990071523A (ko) | 1999-09-27 |
WO1997019097A1 (en) | 1997-05-29 |
EA199800391A1 (ru) | 1999-10-28 |
EP0879241A4 (en) | 2000-04-19 |
JPH11507245A (ja) | 1999-06-29 |
EP0879241A1 (en) | 1998-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9804009A (es) | Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8. | |
IL143921A (en) | Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
PT1187632E (pt) | Tratamento com anticorpos anti-erbb2 | |
PT971585E (pt) | Compostos tetraciclina no tratamento de certos tipos de cancros | |
NO970039D0 (no) | Fremgangsmåte for inhibering av cancer matastaser ved oral administrering av opplöselig modifisert sitruspektin | |
WO2002092854A3 (en) | Genes expressed in breast cancer as prognostic and therapeutic targets | |
IL134445A0 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
MXPA03003632A (es) | Metodo para tratamiento de tumores usando terapia de combinacion. | |
ATE234354T1 (de) | Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens- oligonukleotidbehandelt worden sind. | |
ZA973622B (en) | Use of forms of hyaluronic acid (HA) for the treatment of cancer. | |
WO2000032765A3 (en) | Ribozyme therapy for the treatment and/or prevention of restenosis | |
ATE406160T1 (de) | Verwendung von anastrozol zur behandlung von postmenopausalen frauen mit frühzeitigem brustkrebs | |
MXPA02001204A (es) | Compuestos calciliticos. | |
WO2002032429A3 (en) | Use of inhibitors of progesterone receptor for treating cancer | |
WO2002047710A3 (en) | Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer | |
IL189502A0 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
ZA200108256B (en) | Compositions and methods for the treatment and diagnosis of breast cancer. | |
DE69935156D1 (de) | hCG THERAPIE ZUR BEHANDLUNG VON METASTATISCHEM BRUSTKREBS | |
ZA200203166B (en) | Treatment of cancer. | |
EP0925074A4 (en) | REVERSE OF A CANCER PHENOTYPE BY EXPRESSION INHIBITING PROSTATATUM-INDUCING GENES | |
IL109633A (en) | Tnf receptor promoter | |
WO2001036048A8 (en) | Phorboxazole derivatives for treating cancer | |
WO2002008456A3 (de) | Verfahren zur identifizierung metastasierender tumorzellen | |
WO2001079505A3 (en) | INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY |